NBT Bank N A NY Cuts Stake in Gilead Sciences, Inc. $GILD

NBT Bank N A NY lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,857 shares of the biopharmaceutical company’s stock after selling 132 shares during the period. NBT Bank N A NY’s holdings in Gilead Sciences were worth $982,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in GILD. Southland Equity Partners LLC grew its position in Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares during the period. Twelve Points Wealth Management LLC grew its position in Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after buying an additional 98 shares during the period. Argentarii LLC lifted its holdings in Gilead Sciences by 3.0% during the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares in the last quarter. Investment Research & Advisory Group Inc. lifted its holdings in Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Lodestar Private Asset Management LLC lifted its holdings in Gilead Sciences by 3.6% during the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.67.

Gilead Sciences Price Performance

GILD stock opened at $118.25 on Thursday. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company’s fifty day moving average price is $114.48 and its 200-day moving average price is $110.12. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $146.73 billion, a PE ratio of 23.56, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.